AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15208057 — intervention group
Group type: COMPARATOR
Intervention: Conceptrol (4% nonoxynol-9)
Number of subjects: 49
Study 12133741 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based exercise counseling
Number of subjects: 103
Study 12133741 — intervention group
Group type: COMPARATOR
Intervention: Exercise-related social support
Number of subjects: 103
Study 9853770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal gastroschisis
Number of subjects: 10
Study 9853770 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal fetus)
Number of subjects: 10
Study 7733478 — intervention group
Group type: EXPERIMENTAL
Intervention: Depogen with heparin
Number of subjects: 70
Study 7733478 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 70
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Early quit date (Week 2)
Number of subjects: 95
Study 2925977 — intervention group
Group type: COMPARATOR
Intervention: Late quit date (Week 6)
Number of subjects: 95
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent women
Number of subjects: 95
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent men
Number of subjects: 95
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent subjects
Number of subjects: 95
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake for abstinent women
Number of subjects: 95
Study 2925977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake for abstinent men
Number of subjects: 95
Study 30075741 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate chest x-ray
Number of subjects: 21
Study 30075741 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to NICE guidelines
Number of subjects: 21
Study 30075741 — intervention group
Group type: EXPERIMENTAL
Intervention: Not participating in the trial
Number of subjects: 21
Study 26548854 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated high-pitch dual-source CTA
Number of subjects: 80
Study 26548854 — intervention group
Group type: COMPARATOR
Intervention: Non-ECG-gated high-pitch dual-source CTA
Number of subjects: 80
Study 24193233 — intervention group
Group type: COMPARATOR
Intervention: Saline solution at 5 mL/kg/h
Number of subjects: 60
Study 24193233 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution at 5 mL/kg/h and dopamine 3 mg/kg/min
Number of subjects: 60
Study 24193233 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution at 10 mL/kg/h
Number of subjects: 60
Study 22576884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube current of ≤40 mA
Number of subjects: 80
Study 22576884 — intervention group
Group type: COMPARATOR
Intervention: Mean tube current of 59 ± 20 mA
Number of subjects: 80
Study 22576884 — intervention group
Group type: COMPARATOR
Intervention: Mean fluoroscopy time
Number of subjects: 80
Study 22576884 — intervention group
Group type: COMPARATOR
Intervention: AP diameter
Number of subjects: 80
Study 20233037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, saturated fatty acid (SFA)-rich meal (HFSA)
Number of subjects: 0
Study 20233037 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, monounsaturated fatty acid (MUFA)-rich meal (HFMUFA)
Number of subjects: 0
Study 20233037 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate with 1.24 g high oleic sunflower oil supplement (LFHCC)
Number of subjects: 0
Study 20233037 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate with 1.24 g long chain n-3 poly-unsaturated fatty acid (LC n-3 PUFA) supplement (LFHCCn-3)
Number of subjects: 0
Study 18981325 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 45
Study 18981325 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 45
Study 16097227 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric headgear (AHG)
Number of subjects: 20
Study 16097227 — intervention group
Group type: COMPARATOR
Intervention: Cervical headgear (CHG) combined with removable plate (RP)
Number of subjects: 20
Study 12410780 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (up to 5 days)
Number of subjects: 114
Study 12410780 — intervention group
Group type: COMPARATOR
Intervention: Clonidine and other symptomatic medications (up to 8 days)
Number of subjects: 114
Study 9170485 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxicab voucher
Number of subjects: 104
Study 9170485 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby‐blanket coupon
Number of subjects: 104
Study 9170485 — intervention group
Group type: COMPARATOR
Intervention: Appointment slip (controls)
Number of subjects: 104
Study 2036503 — intervention group
Group type: EXPERIMENTAL
Intervention: Health checks offered systematically to the adult population
Number of subjects: 2205
Study 7273012 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of 3‐4 mg/m2 iv every 10‐14 days
Number of subjects: 60
Study 7273012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 5‐day infusion of 1‐1.2 mg/m2/day every 21 days
Number of subjects: 60
Study 7273012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion after failing to respond to bolus vindesine
Number of subjects: 60
Study 31249395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol diet (HighP)
Number of subjects: 78
Study 31249395 — intervention group
Group type: COMPARATOR
Intervention: Low-polyphenol diet (LowP)
Number of subjects: 78
Study 31675189 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SU) with self-etch (SE) technique
Number of subjects: 63
Study 31675189 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond Elect (PBE) with self-etch (SE) technique
Number of subjects: 63
Study 27379965 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extension exercise in water at 90 b·min
Number of subjects: 17
Study 25698997 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linguistic auditory temporal intervention
Number of subjects: 17
Study 25698997 — intervention group
Group type: COMPARATOR
Intervention: Phonological intervention
Number of subjects: 17
Study 25022119 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated moxa dosage group
Number of subjects: 60
Study 25022119 — intervention group
Group type: COMPARATOR
Intervention: Regular moxa dosage group
Number of subjects: 60
Study 21351218 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Management (PM)
Number of subjects: 28
Study 21351218 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 28
Study 19440837 — intervention group
Group type: EXPERIMENTAL
Intervention: Think Smart curriculum (school-based drug prevention curriculum)
Number of subjects: 0
Study 19440837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17303783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower arm occlusion
Number of subjects: 20
Study 17303783 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm occlusion
Number of subjects: 20
Study 17303783 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg oral dose) before lower arm occlusion
Number of subjects: 20
Study 17303783 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg oral dose) before upper arm occlusion
Number of subjects: 20
Study 15134107 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% xylocaine jelly and 0.5 ml of intracameral 1% lidocaine
Number of subjects: 100
Study 15134107 — intervention group
Group type: COMPARATOR
Intervention: Sub-Tenon infiltration with 2 ml of 2% xylocaine
Number of subjects: 100
Study 11839347 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (multimodality laparoscopic TEP hernia curriculum)
Number of subjects: 21
Study 11839347 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 21
Study 11839347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 10572845 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammographic screening for women aged 40-41
Number of subjects: 195000
Study 10572845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional services offered until age 50)
Number of subjects: 195000
Study 7884084 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 single-photon emission computed tomography (SPECT)
Number of subjects: 321
Study 7884084 — intervention group
Group type: COMPARATOR
Intervention: Exercise electrocardiographic (ECG) response
Number of subjects: 321
Study 7884084 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 321
Study 2190630 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg controlled release (CR) salbutamol tablets twice daily
Number of subjects: 0
Study 2190630 — intervention group
Group type: COMPARATOR
Intervention: 4 mg standard salbutamol tablets four times daily
Number of subjects: 0
Study 677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus cephalothin (T+C)
Number of subjects: 105
Study 677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin (T+G)
Number of subjects: 105
Study 677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin plus gentamicin (C+G)
Number of subjects: 105
Study 31409292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan (50 mg, 100 mg, 200 mg)
Number of subjects: 0
Study 31409292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29166092 — intervention group
Group type: EXPERIMENTAL
Intervention: EmimNTf2 in PES membranes
Number of subjects: 0
Study 29166092 — intervention group
Group type: EXPERIMENTAL
Intervention: DmimNTf2 in PES membranes
Number of subjects: 0
Study 29166092 — intervention group
Group type: EXPERIMENTAL
Intervention: C153 in bulk liquids
Number of subjects: 0
Study 25618318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) 75-mg tramadol/650-mg acetaminophen after a single dose
Number of subjects: 43
Study 25618318 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) 37.5-mg tramadol/325-mg acetaminophen after 2 doses
Number of subjects: 43
Study 25618318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) formulation with food
Number of subjects: 43
Study 25618318 — intervention group
Group type: COMPARATOR
Intervention: Immediate release (IR) formulation with food
Number of subjects: 43
Study 23355060 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800
Study 21285445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric injury prevention program
Number of subjects: 65
Study 21285445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 21285445 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional injury prevention program
Number of subjects: 65
Study 19650753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 45
Study 19650753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 45
Study 19650753 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 45
Study 19650753 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 microg
Number of subjects: 45
Study 17938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose in dialyzing fluid
Number of subjects: 44
Study 17938567 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose in dialyzing fluid)
Number of subjects: 44
Study 15169807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg plus carboplatin and paclitaxel
Number of subjects: 99
Study 15169807 — intervention group
Group type: COMPARATOR
Intervention: Control (carboplatin and paclitaxel alone)
Number of subjects: 99
Study 11878520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 16
Study 11878520 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 16
Study 9766493 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (RA) at doses ranging from 30 to 230 mg/m2/day
Number of subjects: 18
Study 9766493 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (RA)
Number of subjects: 18
Study 9766493 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 18
Study 9266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent A (non-detailed risks)
Number of subjects: 50
Study 9266792 — intervention group
Group type: COMPARATOR
Intervention: Consent B (detailed risks)
Number of subjects: 50
Study 9266792 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without inducible ventricular arrhythmias
Number of subjects: 50
Study 2805362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg sublingually
Number of subjects: 15
Study 2805362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg per os bid for 3 months
Number of subjects: 15
Study 2805362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1111464 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 73
Study 1111464 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 73
Study 1111464 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 73
Study 1111464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and fluoxymesterone
Number of subjects: 73
Study 1111464 — intervention group
Group type: COMPARATOR
Intervention: No poor-risk factors
Number of subjects: 73
Study 1111464 — intervention group
Group type: COMPARATOR
Intervention: At least one poor-risk factor
Number of subjects: 73
Study 1111464 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen level
Number of subjects: 73
Study 31911341 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy stratified by endotype (intervention group)
Number of subjects: 0
Study 31911341 — intervention group
Group type: COMPARATOR
Intervention: Not specified (control group)
Number of subjects: 0
Study 31911341 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified (intervention group)
Number of subjects: 0
Study 31762898 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental impression smears
Number of subjects: 491
Study 31762898 — intervention group
Group type: COMPARATOR
Intervention: Histology
Number of subjects: 491
Study 28929577 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study 28929577 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25981528 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment with customized information and education
Number of subjects: 152
Study 23864139 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon spa therapy
Number of subjects: 681
Study 23864139 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon spa therapy in OA patients
Number of subjects: 681
Study 23864139 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 681
Study 21612644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in RCT setting
Number of subjects: 54
Study 21612644 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture in usual practice
Number of subjects: 54
Study 19883342 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing (PoCT)
Number of subjects: 4381
Study 19883342 — intervention group
Group type: COMPARATOR
Intervention: Pathology laboratory testing
Number of subjects: 4381
Study 16554580 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with an investigational drug
Number of subjects: 30
Study 16554580 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of the maximal diameter of the single largest lesion
Number of subjects: 30
Study 16554580 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple‐lesion measurements
Number of subjects: 30
Study 16554580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐lesion measurements
Number of subjects: 30
Study 15243765 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training on a cycle ergometer (4 sessions per week, 45 min duration) for 12 weeks
Number of subjects: 42
Study 15243765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 11375828 — intervention group
Group type: EXPERIMENTAL
Intervention: IV injection of 2 g propacetamol every 6 h for 3 days after surgery
Number of subjects: 42
Study 11375828 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 42
Study 9404448 — intervention group
Group type: COMPARATOR
Intervention: rhGH therapy (0.25 IU/kg/week sc)
Number of subjects: 148
Study 9404448 — intervention group
Group type: COMPARATOR
Intervention: rhGH therapy
Number of subjects: 148
Study 12061306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (1.2%)
Number of subjects: 0
Study 12061306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2907896 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (human chorionic gonadotropin)
Number of subjects: 243
Study 2907896 — intervention group
Group type: COMPARATOR
Intervention: GnRH (gonadotropin releasing hormone)
Number of subjects: 243
Study 2907896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 29709558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 1204
Study 29709558 — intervention group
Group type: COMPARATOR
Intervention: Non-bursectomy (omentectomy alone)
Number of subjects: 1204
Study 28835465 — intervention group
Group type: EXPERIMENTAL
Intervention: Total modified Sharp/van der Heijde Scores (mSvdHS)
Number of subjects: 363
Study 28835465 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint space narrowing (JSN)
Number of subjects: 363
Study 28835465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosions (ERO)
Number of subjects: 363
Study 28835465 — intervention group
Group type: EXPERIMENTAL
Intervention: mSvdHS in remission analyses
Number of subjects: 363
Study 28835465 — intervention group
Group type: EXPERIMENTAL
Intervention: JSN in remission analyses
Number of subjects: 363
Study 26142691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 164
Study 26142691 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 164
Study 23771585 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing
Number of subjects: 3
Study 23771585 — intervention group
Group type: COMPARATOR
Intervention: Binocular viewing
Number of subjects: 3
Study 23771585 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hand selection with covered right eye leading
Number of subjects: 3
Study 23771585 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hand selection
Number of subjects: 3
Study 19450946 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper setup of SIR (manometer and pop-off valve closed)
Number of subjects: 5
Study 19450946 — intervention group
Group type: COMPARATOR
Intervention: Improper setup of SIR (pop-off valve open)
Number of subjects: 5
Study 19450946 — intervention group
Group type: COMPARATOR
Intervention: Improper setup of SIR (manometer open)
Number of subjects: 5
Study 19450946 — intervention group
Group type: COMPARATOR
Intervention: Improper setup of SIR (both open)
Number of subjects: 5
Study 18294761 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulated acupuncture (EA) weekly for 12 weeks
Number of subjects: 31
Study 18294761 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA) weekly for 12 weeks
Number of subjects: 31
Study 16877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 51
Study 16877657 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 51
Study 16877657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 13678914 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PTCA (balloon angioplasty)
Number of subjects: 2082
Study 13678914 — intervention group
Group type: COMPARATOR
Intervention: Routine stenting
Number of subjects: 2082
Study 11225999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine, mitoxantrone, and dexamethasone (FND) combined with rituximab and maintenance alpha interferon
Number of subjects: 0
Study 11225999 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine, mitoxantrone, and dexamethasone (FND) alone
Number of subjects: 0
Study 9090580 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold T1-weighted FLASH sequence
Number of subjects: 120
Study 9090580 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold T2-weighted TSE sequence
Number of subjects: 120
Study 9090580 — intervention group
Group type: COMPARATOR
Intervention: Non-breath-hold T1-weighted SE sequence
Number of subjects: 120
Study 9090580 — intervention group
Group type: COMPARATOR
Intervention: Non-breath-hold T2-weighted SE sequence
Number of subjects: 120
Study 8405626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 90
Study 8405626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 90
Study 8405626 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 75 mg
Number of subjects: 90
Study 3983422 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (1 g/m2, total 13-14 g/m2) given on every irradiation day
Number of subjects: 179
Study 3983422 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (3 daily fractions of 1.6 Gy for 2 weeks, total dose 48 Gy, boost to about 70 Gy after 3-4 weeks)
Number of subjects: 179
Study 31265730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 1273
Study 31265730 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (IFX 0 mg/kg)
Number of subjects: 1273
Study 29754251 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation and counselling intervention delivered by a pharmacist
Number of subjects: 587
Study 29754251 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 587
Study 26393904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.4 mg and tolterodine 4 mg)
Number of subjects: 80